Demographic and serological data
| Study group | mAb (n = 19) | Placebo (n = 12) | P-value |
|---|---|---|---|
| Gender, n (%) | > 0.999 | ||
| Female | 13 (68.42) | 9 (75) | |
| Male | 6 (31.58) | 3 (25) | |
| Age (years), mean ± SD | 48.65 ± 11.02 | 48.08 ± 12.04 | 0.670 |
| Weight (kg), mean ± SD | 78.15 ± 15.22 | 70.90 ± 13.44 | 0.044 (*) |
| Height (m), mean ± SD | 1.73 ± 0.06 | 1.68 ± 0.11 | 0.154 |
| Smoking habits | > 0.999 | ||
| Non-smoker, n (%) | 15 (78.95) | 10 (83.33) | |
| Smoker, n (%) | 4 (21.05) | 2 (16.67) | |
| Duration of thyroid autoimmunity (month), mean ± SD | 4.37 ± 2.34 | 5.25 ± 2.14 | 0.269 |
| Serology (baseline), mean ± SD | |||
| Serum albumin (32–55 g/L) | 46.74 ± 2.45 | 47.92 ± 2.50 | 0.335 |
| Cholesterol (0–119 mg/dL) | 204.10 ± 52.95 | 206.90 ± 33.43 | 0.727 |
| HDL (< 40 mg/dL) | 62.32 ± 16.27 | 61.58 ± 15.08 | 0.696 |
| LDL (0–129 mg/dL) | 123.80 ± 46.89 | 125.70 ± 32.11 | 0.712 |
| TG (0–199 mg/dL) | 90.58 ± 59.12 | 100.80 ± 44.05 | 0.174 |
| ASAT (0–41 U/L) | 17.79 ± 4.54 | 17.50 ± 3.26 | 0.944 |
| ALAT (0–45 U/L) | 18.68 ± 10.27 | 14.92 ± 6.63 | 0.263 |
| AP (35–104 U/L) | 87.11 ± 29.52 | 78.17 ± 18.30 | 0.453 |
| γGT (0–65 U/L) | 25.00 ± 26.06 | 15.17 ± 5.11 | 0.772 |
| Lymphocytes (abs.) (1–4 × 10E9/L) | 1.90 ± 0.59 | 2.06 ± 0.67 | 0.787 |
| Monocytes (abs.) (0.1–0.9 × 10E9/L) | 0.38 ± 0.22 | 0.35 ± 0.07 | 0.745 |
| Platelets (150–350 × 10E9/L) | 260.40 ± 64.28 | 266.80 ± 58.58 | 0.735 |
| WBC (4–10.7 × 10E9/L) | 6.41 ± 1.75 | 6.31 ± 1.55 | 0.897 |
| CH50 (79–187 uEq/mL) | 111.90 ± 34.07 | 115.80 ± 25.88 | 0.757 |
| C3c (0.9–1.8 g/L) | 1.16 ± 0.17 | 1.17 ± 0.19 | 0.895 |
* Significant difference. n: number of patients/events. γGT: gamma-glutamyltransferase; abs.: absolute number; ALAT: alanine aminotransferase; AP: alkaline phosphatase; ASAT: aspartate aminotransferase; C3c: complement factor 3c; CH50: complement factor CH50; HDL: high-density lipoprotein; LDL: low-density lipoprotein; mAb: monoclonal antibody; SD: standard deviation; TG: triglyceride; WBC: white blood cell